A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs BFKB 8488A (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Genentech
- 27 Apr 2018 Planned number of patients changed from 140 to 160.
- 27 Apr 2018 Planned End Date changed from 22 Jun 2018 to 7 Jun 2019.
- 27 Apr 2018 Planned primary completion date changed from 22 Jun 2018 to 7 Jun 2019.